In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Radius Health Inc.

www.radiuspharm.com

Latest From Radius Health Inc.

Evenity's Postmarketing Requirement Includes Feasibility Component Familiar To Other Osteoporosis Drugs

Amgen might have to conduct a randomized CV outcomes trial for Evenity if it's possible; a Pink Sheet analysis reveals that feasibility has been a factor in the US FDA's postmarketing requirements and commitments for other osteoporosis drugs as well. 
Post Market Regulation & Studies Orthopedics

Amgen Launches Evenity For High-Risk Osteoporosis At $21,900 List Price

Amgen EVP Murdo Gordon highlighted the unmet need for women at high risk, including those with a prior fracture. At $1,825 per month or $21,900 for a one-year course in the US, he says Evenity's cost is much lower versus competing 18- and 24-month anabolic agents.

Launches Pricing Strategies

Companies Reveal Likely EU Review Outcomes Against EMA Advice

The European Medicines Agency asks companies to wait until they know for certain whether their marketing authorization applications will be approved or not before making any public announcement. Despite this, some companies go public as soon as they hear an early, but non-binding, verdict. The Pink Sheet looks at the issue of “trend votes” and at the companies who decide not to wait.

Drug Review Approvals

Radius Braced For Second CHMP No For Abaloparatide

Another expected knockback by the European Medicines Agency's scientific committee is expected for Radius' lead product after the company revealed a negative trend vote for the osteoporosis therapy.

Approvals Policy & Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Anabonix Inc.
  • Nuvios Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Radius Health Inc.
  • Senior Management
  • Jesper Høiland, Pres. & CEO
    Jose Carmona, SVP, CFO
    Lorraine Fitzpatrick, MD, CMO
    Gary Hattersley, PhD, CSO
  • Contact Info
  • Radius Health Inc.
    Phone: (617) 551-4000
    950 Winter St.
    Waltham, MA 02451
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register